Pharma Equity Group A/S (CPH:PEG)

Market Cap	137.48M
Revenue (ttm)	n/a
Net Income (ttm)	-24.42M
Shares Out	1.23B
EPS (ttm)	-0.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,046,099
Average Volume	1,330,103
Open	0.1135
Previous Close	0.1120
Day's Range	0.1135 - 0.1155
52-Week Range	0.0706 - 0.3200
Beta	0.80
RSI	66.31
Earnings Date	May 15, 2025

About Pharma Equity Group

Pharma Equity Group A/S, through its subsidiary, Reponex Pharmaceuticals A/S, a clinical-stage biopharmaceutical company, develops treatments for diseases that have patient and social impact for which current therapy is lacking or in need of improvement. Its products under development that are in Phase II clinical trials include RNX-011 for the treatment of bacterial peritonitis; RNX-021, RNX-022, and RNX-023 for the treatment of Ulcus Cruris chronic skin ulcers; RNX-041 for the treatment of inflammatory bowel diseases, such as chrons and pouch...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 1
• Stock Exchange: Copenhagen Stock Exchange
• Ticker Symbol: PEG